Drug intelligence / Profile preview

Dimercaprol

Development stage
Approved
Lead developer
Oxford University
Modality
Small Molecules
Administration
Intramuscular
01

Overview

Dimercaprol is a small molecule chelating agent developed by British biochemists at Oxford University during World War II as an antidote to the arsenic-based chemical weapon Lewisite. It is primarily used to treat acute poisoning by heavy metals such as arsenic, mercury, gold, and lead (in combination with edetate calcium disodium). Dimercaprol acts by binding to heavy metals through its sulfhydryl groups, forming stable complexes that prevent or reverse the inhibition of sulfhydryl-containing enzymes. These metal-drug complexes are then excreted in the urine. The drug is administered via deep intramuscular injection due to poor oral absorption and can cause significant adverse effects including nephrotoxicity and hypertension. Dimercaprol has also been used off-label for Wilson's disease (copper overload) and has shown effectiveness against certain snake venoms *in vitro*[2][3][4][5].

Brand names
BAL In OilBritish antilewisite
Other names
2,3-dimercapto-1-propanoldimercaprol

Beyond the preview

Go deeper on Dimercaprol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dimercaprol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call